Alogliptin (as benzoate), Pioglitazone (as HCl)

Indications

Alogliptin (as benzoate), Pioglitazone (as HCl) is used for: ALOGLIPTIN
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
PIOGLITAZONE
Treatment of type ii diabetes mellitus

Adult Dose

Child Dose

Renal Dose

Administration

Contra Indications

Precautions

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Alogliptin (as benzoate), Pioglitazone (as HCl) :

Mechanism of Action

ALOGLIPTIN
Alogliptin inhibits dipeptidyl peptidase 4 (dpp-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (gip) and glucagon like peptide 1 ( glp-1). The inhibition of dpp-4 increases the amount of active plasma incretins which helps with glycemic control. Gip and glp-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. Glp-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying
PIOGLITAZONE
Pioglitazone acts as an agonist at peroxisome proliferator activated receptors (ppar) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of ppar-gamma receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic gluconeogenesis. Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an increase in insulin secretion by pancreatic A cells